Medicenna positions itself as a pre-eminent leader in best and first-in-class superkine-based therapeutics. The company is advancing MDNA113, a tumor-targeted bi-functional conditionally activated anti-PD1-IL-2, towards IND-enabling studies with plans to commence a first-in-human trial in H2 2026. The company also maintains MDNA55, an Empowered Superkine for recurrent glioblastoma treatment, which is a fusion of interleukin-4 fused to Pseudomonas exotoxin.
Cyborg Score Rationale
Medicenna demonstrates solid clinical progress with compelling MDNA11 efficacy data and multiple assets in development, but remains pre-commercial with minimal market capitalization (~$21M as of June 2026) and significant execution risks typical of clinical-stage biotech. Key 2026 milestones including the MDNA113 first-in-human trial provide catalysts, though financing and regulatory runway remain concerns.
Top Insights
(January 2026) MDNA11 demonstrated 50% ORR in 2L/3L solid tumors and 42% response rate post-checkpoint inhibitor failure, positioning as best-in-class IL-2 super agonist
(January 2026) Company announced management outlook for 2026 as potentially transformative year with multiple pipeline milestones expected
(February 2026) MDNA113 preclinical data demonstrated favorable tolerability in non-human primates supporting advancement to first-in-human trial scheduled for H2 2026
(April 2026) Company presenting AACR 2026 MDNA113 preclinical data and providing corporate update at Bloom Burton healthcare investor conference
Named Competitors
Keytruda — Checkpoint inhibitor for immuno-oncology
Opdivo — Anti-PD-1 checkpoint inhibitor
Tecentriq — Anti-PD-L1 checkpoint inhibitor
IL-2 therapeutics — Alternative IL-2 agonist approaches
Recent Developments
(January 2026) Announced 2026 outlook and expanded MDNA11 clinical data showing best-in-class IL-2 super agonist potential
(February 2026) Reported Q3 FY2026 financial results and confirmed MDNA113 first-in-human trial planned for H2 2026
(April 2026) Announced presentation at Bloom Burton & Co. Healthcare Investor Conference with latest MDNA113 preclinical data from AACR 2026 meeting
Open the full interactive Medicenna Therapeutics Corp. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.